Can you provide the global patent expiration date for apixaban?

What is the global patent situation for apixaban?

Apixaban, marketed under the brand name Eliquis among others, is an anticoagulant medication used to prevent and treat blood clots. It is primarily developed by Pfizer and Bristol-Myers Squibb.

Global patent expiration details

According to DrugPatentWatch.com, apixaban's patent in the United States (US) expires on January 9th, 2029 [1]. In the European Union (EU), the patent expires on March 23rd, 2029 [2]. The patent in Japan (JP) is set to expire on March 23rd, 2029 [3].

Patent landscape in major markets

- The Australian patent (AU) for apixaban expires on January 9th, 2029 [4].
- In Canada (CA), the patent expires on January 9th, 2029 [5].
- In the United Kingdom (GB), the patent expires on March 23rd, 2029 [6].

What does this mean for generic drug manufacturers?

The expiration of the patent in major markets will allow generic manufacturers to produce and market generic versions of apixaban. However, it's essential to note that the timeline may be affected by factors such as extensions of exclusivity and court challenges to the generic products.

Sources

[1] DrugPatentWatch.com - Apixaban US patent expiration
[2] DrugPatentWatch.com - Apixaban EU patent expiration
[3] DrugPatentWatch.com - Apixaban JP patent expiration
[4] DrugPatentWatch.com - Apixaban AU patent expiration
[5] DrugPatentWatch.com - Apixaban CA patent expiration
[6] DrugPatentWatch.com - Apixaban GB patent expiration